A recent study reported that GLPG‐0187, an integrin/TGF‐β1 inhibitor, blocks SARS‐CoV‐2 Delta and Omicron pseudovirus infection of airway epithelial cells, effectively alleviating the severity of COVID‐19.390. This evidence concerns the gene TGFB1 and COVID-19.